Mabpharm (02181) Releases February 2026 Monthly Return on Movements in Securities
Bulletin Express
Mar 03
Mabpharm Limited (02181) announced its monthly return for February 2026, reporting an authorized share capital of 50.00 billion ordinary shares at a par value of USD 0.0001, totaling USD 5.00 million.
The total issued shares remain at 4.12 billion with zero treasury shares. The public float requirement stands at 25%, with compliance confirmed. Meanwhile, 72.67 million share options remain outstanding under the share option scheme, with no changes during the month. There are no warrants, convertibles, or other share arrangements. The announcement was submitted on 03 March 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.